Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -64,080 | -6,182 | 30,312 | 17,371 | 854,029 |
| Depreciation Amortization | 113,194 | 85,332 | 57,092 | 28,656 | 105,739 |
| Income taxes - deferred | -15,608 | -12,020 | 1,204 | 3,335 | -889,993 |
| Accounts receivable | 65,574 | 65,513 | 17,420 | 40,294 | -59,035 |
| Other Working Capital | 66,034 | 66,150 | -1,848 | 8,270 | -224,935 |
| Other Operating Activity | 139,422 | 94,563 | 92,116 | 15,586 | 299,560 |
| Operating Cash Flow | $304,536 | $293,356 | $196,296 | $113,512 | $85,365 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -246,094 | -235,032 | -135,631 | -42,534 | 26,171 |
| PPE Investments | -95,578 | -66,840 | -48,106 | -25,507 | -114,312 |
| Purchase Sale Intangibles | -23,647 | -8,026 | -6,400 | -2,747 | 43,952 |
| Other Investing Activity | -24,641 | -9,020 | -7,308 | -2,747 | 34,520 |
| Investing Cash Flow | $-366,313 | $-310,892 | $-191,045 | $-70,788 | $-53,621 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 585,752 |
| Debt Repayment | -3,039 | -2,492 | -1,941 | -1,084 | -381,909 |
| Common Stock Issued | 49,194 | 32,877 | 27,640 | 5,817 | 71,913 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -50,000 |
| Other Financing Activity | -46,203 | -44,829 | -39,112 | -29,097 | -44,638 |
| Financing Cash Flow | $-48 | $-14,444 | $-13,413 | $-24,364 | $181,118 |
| Exchange Rate Effect | -57 | -35 | 537 | -205 | -1,150 |
| Beginning Cash Position | 649,158 | 649,158 | 649,158 | 649,158 | 437,446 |
| End Cash Position | 587,276 | 617,143 | 641,533 | 667,313 | 649,158 |
| Net Cash Flow | $-61,882 | $-32,015 | $-7,625 | $18,155 | $211,712 |
| Free Cash Flow | |||||
| Operating Cash Flow | 304,536 | 293,356 | 196,296 | 113,512 | 85,365 |
| Capital Expenditure | -95,578 | -66,840 | -48,106 | -25,507 | -114,312 |
| Free Cash Flow | 208,958 | 226,516 | 148,190 | 88,005 | -28,947 |